First Graphite enters trading halt ahead of capital raising


Published 24-JAN-2017 16:17 P.M.


1 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

First Graphite (ASX:FGR) is advancing a new energy storage device, a supercapacitor battery that it believes will be superior to existing chemical batteries.

First Graphite is playing in the graphite space in Sri Lanka, where it is sourcing premium quality graphite from Sri Lanka, and transforming it into graphene.

The company requested a trading halt on Tuesday morning, stating its intention to raise approximately $3 million by the placement of 32 million shares at 11¢ each, being an increase of just over 10% in the issued capital.

The placement is open to Sophisticated Investors at a 10.6% discount to 5 day VWAP share price, with Warwick Grigor from Far East Capital handling the lead manager’s role.

It is anticipated that funds raised through the capital raising will be used in the development of this technology through the acquisition of graphene related IP, allowing the company to further advance graphene testing and production capability.

Prospective investors can also gain access to the raising through capital raising and IPO platform, which currently also lists Raptor Resources IPO as a current deal and has previously raised money for Rotogro, Cobalt Blue, Broo Limited and Birimian.

Remember, however, that FGR is an early stage company and investment success is no guarantee. Apply caution to your investment decision with regard to this stock.

First Graphite has signed a sales agreement with the Sri Lankan Government owned KGLL to purchase 100% of the Kahatagaha premium grade vein graphite for a period of two years.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free